New Delhi, Oct 16 (IANS) New drug rules and regulatory procedures introduced in India have promoted scientific and ethical research at par with global expectation and international practices, the government said on Wednesday.
Addressing at the 19th International Conference of Drug Regulatory Authorities (ICDRA) in the national capital, Union Minister of State for Health and Family Welfare, Anupriya Singh Patel, said the conference is crucial in sharing knowledge, building partnerships and working in harmonisation to ensure safe and effective medicines for everyone.
“Our efforts can lead to better health outcomes for people all over the world. The ICDRA is not just a conference; it is a chance for us to collaborate, innovate, and support one another in our shared mission for better health for all”, said the minister.
The conference is being hosted for the first time in India by the Central Drugs Standard Control Organisation (CDSCO), in collaboration with the World Health Organisation (WHO).
The country has introduced New Drugs and Clinical Trial Rules 2019 and Medical Device Rules 2017.
According to the minister, the medical device rules in India include risk-based classification, bringing all devices under regulation through registration and framing regulatory pathway.
“There is robust pre-approval and post approval regulatory procedures of all medical devices, diagnostics managing product lifecycle indicating robust control. We are collaborating with international organisations such as the International Medical Device Regulators Forum (IMDRF), ISO, WHO and regional network like SEARN (South-East Asia Regulatory Network) to harmonise regulatory requirements in the area of medical devices and diagnostics,” Patel told the gathering.
India has recently been recognised as an affiliate member of IMDRF.
“Recognition of Indian Pharmacopoeia by the Pharmacopoeial Discussion Group (PDG) is another milestone marking the harmonisation and recognition of regulatory standards”, the minister informed.
On the Centre’s commitment to healthcare, the minister said that programmes like Ayushman Bharat ensure that over 500 million people have access to quality healthcare.
Dr VK Paul, Member (Health), NITI Aayog, said “quality medicines improve the quality of life, human productivity as well as the way of life.”
He highlighted the efforts being taken on healthcare sector by the present government such as the launch of the world’s largest health assurance scheme and a massive effort being taken in digital health.
Dr Paul informed that India licensed eight vaccines for use during the pandemic through a proper regulatory process.
Dr Rajiv Bahl, Secretary, Department of Health Research and DG, ICMR, that in the first three months of the pandemic, India developed indigenous tests at one-fortieth of the cost.
“Similarly, within nine months of the pandemic, India approved a Covid-19 vaccine,” he said, adding that three diagnostic tests have also been developed for MPox which were approved by CDSCO.
Dr Yukiko Nakatini, Assistant Director-General, WHO noted that one urgent need highlighted by the pandemic was the need for a strong regulatory system.
Dr Yukiko also congratulated India for its achievement of retaining ‘Maturity level III’ for vaccine regulation.
Kimberlee Trzeciak, Deputy Commissioner, US Food and Drug Administration (FDA) highlighted the opportunities and risks brought about by the introduction of advanced drug manufacturing practices as opposed to the traditional methods.
–IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
